Developing the Future of Hair Therapy
Developing the Future of Hair Therapy
R&D PIPELINE
Precision Pharmacology for Hair Regeneration
The Challenge
Current treatments for hair loss and greying often suffer from poor patient compliance, systemic side effects, or a lack of clinical efficacy specifically tailored to the unique biological needs of women. For hair greying, the market lacks a definitive pharmaceutical-grade solution that addresses the root cause of pigment loss.
BioQ Innovation
Our technology platform focuses on two first-in-class or best-in-class therapeutic candidates that leverage sophisticated formulation chemistry to enhance bioavailability and targeted action.
BQ-001 (Female Pattern Hair Loss)
A first-in-class injectable, sustained-release therapeutic designed to address female pattern hair loss. By utilizing a proprietary delivery vehicle, BQ-001 provides a targeted, long-acting solution that maintains optimal follicular concentrations of active compounds for up to three months. This injectable approach eliminates the compliance barriers and efficacy limitations associated with traditional topical regimens that interfere with a woman's hair styling and lifestyle, offering a professional-grade alternative in the high-growth anti-aging hair market.
BQ-002 (Grey Hair - Canities)
A first-in-class injectable, sustained-release therapeutic designed to re-pigment grey hair. BQ-002 addresses the underlying biology of canities, offering a biological alternative to temporary synthetic dyes that damage hair. This injectable approach optimizes patient compliance and efficacy, delivering sustained hair re-pigmentation for up to three months while maintaining a superior safety profile compared to systemic treatments.
World-Class Leadership & Expertise
BioQ is led by a global team of entrepreneurs, clinical experts, and seasoned operators with 120+ years of combined industry experience. Our leadership brings a distinguished track record of moving breakthrough biopharmaceutical technologies from bench to global markets.
Proven Excellence in Innovation
Our founders and core team have built a formidable foundation of scientific and operational success:
-
Product Development: Over 40 drugs and devices successfully developed and brought to market.
-
Clinical Rigor: Directed and executed more than 100 clinical trials.
-
Intellectual Property: Authors and inventors of over 100 filed patents.
-
Strategic Exits: A winning combination of 6+ successful exits and over 20 licensing deals.
Prof Andy Goren, MD
Founder, Chief Medical Officer
A world-renowned expert in hair loss and a serial entrepreneur in the field. Prof. Goren was the first to develop a clinical genetic test for minoxidil response. He is an esteemed speaker at IMCAS and a visiting professor at numerous prestigious universities worldwide.
Raj Airey
Founder, Corporate Development & Strategy
With 30 years in the biomedical business space, Raj is a veteran venture builder and investor who has successfully managed three high-growth businesses. He previously served as Country Manager for Pfizer (Europe) and Baxter Healthcare (India).
Yotam Levin, MD, MBA
Founder & President
Dr. Levin brings over 20 years of CEO experience in taking complex products from concept to market. A prolific co-inventor of 86 patent filings for drug-device combinations, he developed the smallest FDA-cleared injection device for the skin.
Prof. Heinz Haenel
Co-Founder, Operations Lead
A former Project Director at Sanofi with 38 years of drug development expertise. Prof. Haenel has led multinational teams in the development of products across dermatology and insulin therapy, seeing them through to global market release.
Shimon Amsalem, PhD
Formulation Expert
A renowned expert in formulation, Dr. Amsalem has participated in the development of eight marketed products in the US and EU. He is the founder of Nextar (CDMO) and has successfully brought multiple products through to clinical trials.
Monica Naegle
Vice President of Finance and Operations
Monica has over 15 years of experience in the biotech industry and is a results-driven executive with extensive expertise leading finance and operations across clinical laboratory start-ups, manufacturing, and administrative oversight environments.
Investor Relations
We invite qualified investors and potential strategic partners to reach out for detailed information regarding our current funding round, clinical milestones, and long-term exit strategy. Please contact our corporate development team to request a formal briefing or to schedule a meeting at info@bioq.com.